Novel checkpoint inhibitors hit by another setback, but opportunities remain
A trial of novel checkpoint inhibitor monalizumab has been terminated after the drug failed to meet the efficacy threshold.
By
Global
Latest in
Global
Findings suggest urban-rural divide in early-onset dementia diagnosis
The geographic disparities behind early-onset dementia highlight the need to bridge the urban-rural divide.
By
Back to the future: the evolution of clinical conference topics in the past decade
With the 20th birthday of the renowned Clinical Trial Supply East Coast conference in October, we look at topic changes…
By
Industrial automation hiring in clinical trial operations rose to a year-high in July 2022
The latest figure is higher than the 49.7% of companies who were hiring for industrial automation related jobs a year…
By
Filings buzz in pharma: 30% decrease in AI mentions in Q2 of 2022
The frequency of sentences related to AI between July 2021 and June 2022 was 421% higher than in 2016.
By
Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
By
Future of work hiring in clinical trial operations rose in July 2022
The latest figure is higher than the 42.4% of companies who were hiring for future of work related jobs a…
By
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five…
By